Publications by authors named "Nancy Dgetluck"

Claim this Profile
C
Cannabinoid receptor 2 agonist, lenabasum, for the treatment of pulmonary exacerbations in cystic fibrosis.
Natalie E West, Michael W Konstan, Patrick A Flume, Donald R VanDevanter, Amalia Magaret, Nancy Dgetluck

J Cyst Fibros· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis.
Robert Spiera, Masataka Kuwana, Dinesh Khanna, Laura Hummers, Tracy M Frech, Nancy Dgetluck

Arthritis Rheumatol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with Dermatomyositis with Refractory Skin Disease: A Randomized Clinical Trial.
Victoria P Werth, Emily Hejazi, Sandra M Pena, Jessica Haber, Majid Zeidi, Nancy Dgetluck

J Invest Dermatol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomised, double-blind, placebo-controlled phase 3 study of lenabasum in diffuse cutaneous systemic sclerosis: RESOLVE-1 design and rationale.
Robert Spiera, Dinesh Khanna, Masataka Kuwana, Daniel E Furst, Tracy M Frech, Nancy Dgetluck

Clin Exp Rheumatol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply.
Robert Spiera, Lorinda Chung, Tracy Frech, Robyn Domsic, Vivien Hsu, Nancy Dgetluck

Arthritis Rheumatol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of lenabasum in a phase 2 randomized, placebo-controlled trial in adults with cystic fibrosis.
James F Chmiel, Patrick Flume, Damian G Downey, Allen J Dozor, Carla Colombo, Nancy Dgetluck

J Cyst Fibros· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Efficacy of Lenabasum in a Phase II, Randomized, Placebo-Controlled Trial in Adults With Systemic Sclerosis.
Robert Spiera, Laura Hummers, Lorinda Chung, Tracy M Frech, Robyn Domsic, Nancy Dgetluck

Arthritis Rheumatol· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an α7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia.
Richard S E Keefe, Herbert A Meltzer, Nancy Dgetluck, Maria Gawryl, Gerhard Koenig

Neuropsychopharmacology· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reliability, validity and treatment sensitivity of the Schizophrenia Cognition Rating Scale.
Richard S E Keefe, Vicki G Davis, Nathan B Spagnola, Dana Hilt, Nancy Dgetluck

Eur Neuropsychopharmacol· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacodynamics, pharmacokinetics, safety, and tolerability of encenicline, a selective α7 nicotinic receptor partial agonist, in single ascending-dose and bioavailability studies.
Ann J Barbier, Martijn Hilhorst, André Van Vliet, Peter Snyder, Michael G Palfreyman, Nancy Dgetluck

Clin Ther· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circadian rhythms in cognitive functioning among patients with schizophrenia: impact on signal detection in clinical trials of potential pro-cognitive therapies.
Michael R Hufford, Vicki G Davis, Dana Hilt, Nancy Dgetluck, Yona Geffen

Schizophr Res· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Normalizing effects of EVP-6124, an α-7 nicotinic partial agonist, on event-related potentials and cognition: a proof of concept, randomized trial in patients with schizophrenia.
Sheldon H Preskorn, Maria Gawryl, Nancy Dgetluck, Michael Palfreyman, Lance O Bauer

J Psychiatr Pract· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hemodynamic effects of once-daily tadalafil in men with signs and symptoms of benign prostatic hyperplasia on concomitant α1-adrenergic antagonist therapy: results of a multicenter randomized, double-blind, placebo-controlled trial.
Evan Goldfischer, John J Kowalczyk, William R Clark, Erin Brady, Michael Anne Shane, Nancy Dgetluck

Urology· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis